Press releases

10 May, 2019

Regulatory

NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA

Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational ...

30 April, 2019

Regulatory

NeuroVive announces ruling from Supreme Court in case between the company and CicloMulsion AG

Lund, 30 April, 2019— NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the Supreme Court had delivered its ruling concerning arbitration between NeuroVive and Cic ...

25 April, 2019

Regulatory

Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 25 April 2019, NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today on 25 April 2019 held its Annual General Meeting (AGM). A summary of the resolutions follows.

25 March, 2019

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (publ)

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 25, 2019, at 4 pm at Medicon Village, Scheelev ...

19 March, 2019

Regulatory

NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study

Lund, Sweden, 19 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company’s KL1333 phase Ia/b study has been screen ...

21 February, 2019

NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds

Lund, Sweden, 21 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of ...

25 January, 2019

Regulatory

NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.

17 January, 2019

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 January 2019, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. All resolutions were unani ...

11 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 1 pm on Thursday 17 January 2019 at Medicon Village, Scheelevägen ...

11 December, 2018

Regulatory

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018:

10 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

15 November, 2018

Regulatory

NeuroVive receives Vinnova funding to support development of NV354, a novel treatment for genetic mitochondrial disorders

Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...